Virtual Assay drug screening software V.3.0
Easy to use drug screening software that allows users to produce a population of models for quantitative prediction of drugs effects on cellular function.
Home>Pharma/Biopharma
The therapeutic potential of chemically synthesised oligonucleotides
Researchers at the University of Oxford have developed a chemical synthesis strategy for producing DNA incorporating non-natural backbone structures and locked nucleic acid (LNA) sugars which convey desirable properties such as more selective and robust binding to complementary nucleic acids and greater resistance to enzymatic degradation.
Acute myeloid leukaemia prognostic and diagnostic screening
Oxford researchers, in collaboration with the University of Birmingham, have discovered novel combinations of cell-surface biomarkers (CD molecules) that allow AML to be stratified into 3 different molecular sub-types to allow targeted treatment and better monitoring of treatment response.
Hepatitis C vaccine
A viral-vectored vaccine incorporating a novel immunogen for a pan-genotypic Hepatitis C protection based on genomic segments that are conserved between HCV genotypes.
The Rare UK Diseases Study platform
A bespoke web-based platform that allows for online registration, record and management of patient data within a dynamic consent framework.
Oncostatin-M: A novel therapeutic target for inflammatory bowel disease
Oxford researchers have discovered a novel target that could lead to a whole new class of effective inflammatory bowel disease drugs being developed.
PubMLST molecular typing databases
Multi locus sequence typing (MLST) and whole genome MLST typing for molecular characterisation of bacteria
Manufacturing continuous nanofibrous filaments
A method for the production of continuous nanofibrous filaments
Delivering therapeutics to hard-to-treat secondary brain tumours
A method to selectively increase the permeability of the blood-brain barrier at sites of secondary brain tumours.
Improved inflammation imaging
New Lewis-sugar based MRI contrast agents provide excellent diagnostic images for inflammatory diseases.
© Oxford University Innovation